About ReShape
ReShape is a company based in San Clemente (United States) founded in 2005 was acquired by EnteroMedics in October 2017. ReShape has raised $90.32 million across 9 funding rounds from investors including SVB, New Leaf Venture Partners and Oxford Finance. ReShape offers products and services including LAP-BAND, ReShape Vest, and ReShape Care. ReShape operates in a competitive market with competitors including Apollo Endo, USGI Medical, Vibrynt, Satiety and Barosense, among others.
- Headquarter San Clemente, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Reshape Lifesciences Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$90.32 M (USD)
in 9 rounds
-
Latest Funding Round
$11 M (USD), Debt – Conventional
Feb 13, 2017
-
Investors
SVB
& 8 more
-
Employee Count
Not available
-
Acquired by
EnteroMedics
(Oct 03, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ReShape
ReShape offers a comprehensive portfolio of products and services, including LAP-BAND, ReShape Vest, and ReShape Care.
Minimally invasive device for long-term obesity treatment.
Laparoscopically implanted system for rapid weight loss.
Virtual tele-health coaching for sustained weight management.
Funding Insights of ReShape
ReShape has successfully raised a total of $90.32M across 9 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $11 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ReShape
ReShape has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, New Leaf Venture Partners and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Endeavour Vision is focused on transformative healthcare technology investments.
|
Locked | Locked | Locked | |
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked |
Investor details for ReShape
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ReShape
Investment portfolio details for ReShape
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ReShape
Detailed financials for ReShape
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Reshape Comparisons
Peer comparison for ReShape
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ReShape
ReShape operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Apollo Endo, USGI Medical, Vibrynt, Satiety and Barosense, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic devices for obesity and GI disorders are developed.
|
|
| Locked | Locked | Locked |
Incisionless operating platform for weight loss surgery
|
|
| Locked | Locked | Locked |
Provides durable coat hooks and storage solutions for home use.
|
|
| Locked | Locked | Locked |
Develops a device for transoral gastroplasty to induce satiety through endoscopic methods.
|
|
| Locked | Locked | Locked |
Restrictive gastric implants and procedures are developed to induce satiety.
|
Detailed competitors of ReShape
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Reshape
Complete news archive for ReShape
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReShape
ReShape was founded in 2005 and raised its 1st funding round 2 years after it was founded.
ReShape is headquartered in San Clemente, United States. It is registered at San Clemente, California, United States.
Michael Mangano is the current CEO of ReShape.
ReShape is a funded company, having raised a total of $90.32M across 9 funding rounds to date.
ReShape Medical has developed the ReShape Dual Balloon, a dual intra-gastric balloon system for weight loss. It is inserted into the stomach through an endoscopic procedure and filled with saline (salt water). The balloons remain in the stomach for six months and help reduce hunger. Insertion of the gastric balloon is completed in about 20 minutes, with no hospital stay required. The company has received FDA approval for its ReShape Integrated Dual Balloon system.
ReShape's top competitors include Apollo Endo, USGI Medical and Barosense.
ReShape offers LAP-BAND, ReShape Vest, and ReShape Care.
ReShape has 9 investors. Key investors include SVB, New Leaf Venture Partners, Oxford Finance, EnteroMedics, and HealthCor Partners.